This provider's $17.3M in total Medicare payments ranks in the 94th percentile of Clinical Laboratory providers nationally.
Medicare payments to this provider grew 1429% from 2020 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 742% in 2021
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2020 | $59.35 | $42.09 | 1.41x | $17.26 | $396.4K | 9.4K | 9 |
| 2021 | $89.41 | $42.71 | 2.09x | $46.70 | $3.3M | 78.2K | 35 |
| 2022 | $96.39 | $42.49 | 2.27x | $53.90 | $7.5M | 175.6K | 25 |
| 2023 | $97.55 | $45.87 | 2.13x | $51.68 | $6.1M | 132.2K | 44 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 70.1K | $5.2M | $74.10 | 2.70x |
| 87798 | Detection test by nucleic acid for organism, amplified probe technique | 50.0K | $1.7M | $34.46 | 2.00x |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | 69.4K | $1.7M | $24.66 | 2.03x |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 62.9K | $1.6M | $25.09 | 1.90x |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 19.6K | $983.5K | $50.28 | 1.99x |
| 87502 | Detection test by nucleic acid for multiple types influenza virus | 9.0K | $846.5K | $94.39 | 1.42x |
| 87150 | Identification of organisms by genetic analysis, amplified probe technique | 21.6K | $746.8K | $34.64 | 2.01x |
| 87481 | Detection test for candida species (yeast), amplified probe technique | 17.3K | $600.9K | $34.64 | 2.04x |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 2.4K | $593.3K | $243.95 | 2.05x |
| 87634 | Detection test by nucleic acid for respiratory syncytial virus, amplified probe technique | 7.2K | $495.8K | $69.26 | 1.99x |
| 87636 | Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19) and influenza virus types a and b | 2.1K | $295.2K | $139.65 | 1.79x |
| 87486 | Detection test by nucleic acid for chlamydia pneumoniae, amplified probe technique | 7.5K | $260.5K | $34.64 | 2.00x |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 11.0K | $258.5K | $23.40 | 1.81x |
| 87637 | Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | 1.8K | $246.3K | $139.78 | 1.79x |
| 87631 | Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets | 1.6K | $225.9K | $141.39 | 1.87x |
| 87581 | Detection test by nucleic acid for mycoplasma pneumoniae (bacteria), amplified probe technique | 6.3K | $217.9K | $34.57 | 1.99x |
| 87503 | Detection test by nucleic acid for multiple types influenza virus, each additional influenza virus type or sub-type | 6.7K | $194.0K | $28.89 | 1.99x |
| 87498 | Detection test by nucleic acid for enterovirus (intestinal virus), amplified probe technique | 4.7K | $164.3K | $34.60 | 1.96x |
| 80307 | Testing for presence of drug, by chemistry analyzers | 2.4K | $149.2K | $61.39 | 2.04x |
| 87651 | Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 3.9K | $134.9K | $34.68 | 2.04x |
This provider submits charges 2.17 times higher than what Medicare actually pays.
A markup ratio of 2.17x means for every $100 Medicare pays, this provider initially charges $217. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in CA for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Genomic Health, Inc. | Redwood City, CA | $887.6M | ✓ Clear |
| Unilab Corporation | West Hills, CA | $868.8M | ⚠️ Flagged |
| Caredx Inc. | Brisbane, CA | $751.0M | ✓ Clear |
| Laboratory Corporation Of America | San Diego, CA | $592.4M | ⚠️ Flagged |
| Millennium Health, Llc | San Diego, CA | $587.9M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data